Overview
Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Its network of partners includes all Top 20 Pharma and more than 800 biotechnology companies, academic institutions, and other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. With
...
Read More operations in six countries, Evotec generates some 60% of total revenue from the US. Evotec originally was founded as Evotec BioSystems GmbH in Hamburg, Germany, in 1993.
Read Less
Read More operations in six countries, Evotec generates some 60% of total revenue from the US. Evotec originally was founded as Evotec BioSystems GmbH in Hamburg, Germany, in 1993.
Read Less
Christian Wojczewski
See more contacts
Scientific Research and Development Services
,
Pharmaceutical and Medicine Manufacturing
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
,
Commercial physical research
See All Industries , Medicinal chemicals , Diagnostic substances , Medical research Medicinals and botanicals
See Fewer Industries
See All Industries , Medicinal chemicals , Diagnostic substances , Medical research Medicinals and botanicals
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Estimated
?
Actual
$842.80 million
Actual
1.99%
$1,912
DEC
?
?
XETRA:EVT
Contacts
Get in Touch with 20 Principals*
-
Christian WojczewskiChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$842.80 million
USD
Actual
1 USD = 0.9456 EUR
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $19 | $39 | $218 |
| Net Investing Cash | -$75 | -$14 | -$437 |
| Net Financing Cash | -$171 | $76 | -$61 |
| Net Change in Cash | -$227 | $101 | -$280 |
| Cash at Beginning of Period | $540 | $439 | $740 |
| Cash at End of Period | $324 | $540 | $439 |
| Capital Expenditure | -$140 | -$228 | -$192 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $324 | $540 | $424 |
| Accounts Receivable | $123 | $104 | $182 |
| Inventories | $33 | $33 | $32 |
| Other Current Assets | $241 | $278 | $498 |
| Asset Summary | |||
| Total Current Assets | $721 | $955 | $1,135 |
| Tangible Fixed Assets | $871 | $853 | $688 |
| Intangible Assets | $28 | $16 | $25 |
| Total Assets | $1,913 | $2,252 | $2,257 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $91 | $142 | $103 |
| Short-Term Debt | $54 | $158 | $2 |
| Other Current Liabilities | $220 | $192 | $253 |
| Liability Summary | |||
| Total Current Liabilities | $364 | $491 | $357 |
| Long-Term Debt | $415 | $505 | $347 |
| Other Long-Term Liabilities | $1 | $1 | $1 |
| Total Liabilities | $1,015 | $1,198 | $1,132 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $188 | $187 | $187 |
| Retained Earnings | -$711 | -$504 | -$415 |
| Equity Summary | |||
| Total Equity | $1,007 | $1,184 | $1,255 |
| Shares Outstanding | 177,553,456 | 177,185,736 | 176,952,653 |